文献速递免疫规划慢病防控与筛查

接受系统性治疗的银屑病患者接种科兴与辉瑞/BioNTech mRNA疫苗的免疫原性、效力及安全性:一项前瞻性队列研究

Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
PubMed 文献 · Vaccine · 2023-06-03

该非干预性前瞻性队列研究纳入89例使用生物制剂或甲氨蝶呤的银屑病患者及40名对照,接种两剂科兴灭活疫苗或辉瑞/BioNTech mRNA疫苗。科兴疫苗后患者抗刺突及中和抗体滴度显著低于对照,而mRNA疫苗后两组抗体水平相当;英夫利西单抗与灭活疫苗应答减弱相关,mRNA疫苗不良反应更常见但均非严重。

要点

  • 银屑病患者接种科兴疫苗后抗刺突抗体中位数57.92 U/mL,显著低于对照的125.4 U/mL。
  • 辉瑞/BioNTech疫苗后患者与对照抗刺突抗体中位数分别为2,080 U/mL与2,976.5 U/mL,差异无统计学意义。
  • 英夫利西单抗与灭活疫苗应答减弱相关;mRNA疫苗不良反应更常见但均非严重。

核心结论

  • 使用生物制剂和甲氨蝶呤的银屑病患者对mRNA疫苗应答与对照相似,但对灭活疫苗应答较弱。
  • 英夫利西单抗降低对灭活疫苗的应答。
  • mRNA疫苗不良反应更频繁,但均非严重。

研究设计与样本

  • 非干预性前瞻性队列研究,纳入89例患者和40名对照,接种两剂科兴灭活疫苗或辉瑞/BioNTech mRNA疫苗。
  • 在第二剂接种前及接种后3至6周分析抗刺突抗体和中和抗体,并评估不良反应和有症状COVID-19。

主要发现

  • 科兴疫苗后患者抗刺突抗体中位数57.92 U/mL vs 对照125.4 U/mL,中和抗体中位数1/6 vs 1/32,p < 0.05。
  • 患者达到高滴度抗刺突抗体水平的比例较低(25.6% vs 50%)。
  • 辉瑞/BioNTech疫苗后患者与对照抗刺突抗体中位数2,080 U/mL vs 2,976.5 U/mL,中和抗体中位数1/96 vs 1/160,p > 0.05。
  • 辉瑞/BioNTech疫苗后高滴度抗刺突抗体及中和抗体产生率在患者与对照间相当(95.2% vs 100%,30.4% vs 50.0%,p > 0.05)。
  • 发现9例(10.1%)COVID-19病例,均为轻型;银屑病复发见于6.74%,多发生在辉瑞/BioNTech疫苗后。

关键数值与推荐

  • 科兴疫苗后患者抗刺突抗体中位数57.92 U/mL vs 对照125.4 U/mL,中和抗体中位数1/6 vs 1/32,p < 0.05。
  • 患者达到高滴度抗刺突抗体水平比例25.6% vs 对照50%。
  • 辉瑞/BioNTech疫苗后患者抗刺突抗体中位数2,080 U/mL vs 对照2,976.5 U/mL,中和抗体中位数1/96 vs 1/160,p > 0.05。
  • 辉瑞/BioNTech疫苗后高滴度抗刺突抗体及中和抗体产生率患者95.2% vs 对照100%,患者30.4% vs 对照50.0%,p > 0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Evidence of immune response to COVID-19 vaccine in psoriasis patients on biological agents is lacking. This study aimed to evaluate SARS-CoV-2 antibody levels following vaccination with CoronaVac or Pfizer/BioNTech mRNA in patients using biological agents or methotrexate, high-titer antibody levels achievement rate, and impact of medications on immunogenicity. METHODS: This noninterventional, prospective cohort study included 89 patients and 40 controls vaccinated with two doses of inactivated (CoronaVac) or Pfizer/BioNTech mRNA vaccines. Anti-spike and neutralising antibodies were analysed before and three to six weeks after the second dose. Adverse effects and symptomatic COVID-19 were assessed. RESULTS: Median anti-spike and neutralising antibody titers after CoronaVac were significantly lower in patients than controls (57.92 U/mL vs 125.4 U/mL, and 1/6 vs 1/32, respectively, p < 0.05). Patients were less likely to achieve high-titer anti-spike antibody levels (25.6 % vs 50 %). Infliximab was associated with attenuated vaccine response. Pfizer/BioNTech vaccine induced comparable median anti-spike (2,080 U/mL vs 2,976.5 U/mL,) and neutralising antibody levels (1/96 vs 1/160) in patients and controls, respectively (p > 0.05). High-titer anti-spike and neutralising antibodies development rates were comparable among patients and controls (95.2 % vs 100 %, and 30.4 % vs 50.0 %, respectively, p > 0.05). Nine (10.1 %) COVID-19 cases- all mild - were identified. Psoriasis flare was seen in 6.74 %, mostly after Pfizer/BioNTech vaccine. CONCLUSION: Psoriasis patients treated with biological agents and methotrexate developed similar response to mRNA vaccine but weaker response to inactivated vaccine. Infliximab reduced response to the inactivated vaccine. Adverse effects were more frequent with mRNA vaccine, but none was severe.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ergun T, Hosgoren Tekin S, Apti Sengun O, et al. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study. Vaccine. 2023. PMID: 37277251. doi:10.1016/j.vaccine.2023.05.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。